Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now discontinuing its patch pump program as part of a broader restructuring ...

As a result of the restructuring, Embecta expects pretax savings between $7 million and $8 million during the second half of ...

Embecta now expects revenues between $1.073 billion and $1.09 billion. This would mark a sales dip of between 4.4% and 2.9% year-over-year. It’s also a decrease from previous projections for between ...

CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio and strategy, we have decided to discontinue our insulin patch pump program ...

Embecta stock may seem undervalued at first glance, but heavy debt, declining pen needle revenues, and competition signal ...

Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes. The fully disposable device ...

embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.

CEO Dev Kurdikar emphasized three strategic priorities shaping Embecta’s transformation ... The restructuring plan tied to the discontinued insulin patch pump program is substantially complete ...

Embecta (NASDAQ:EMBC) said it has submitted a 510(k) premarket application to the FDA for approval of its insulin patch pump for the treatment of type 2 diabetes. The company added that it plans ...